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Background 
Alterations on inflammatory pathways lead to aberrant expression of cyclooxygenase-2 
(COX-2) in colon carcinogenesis (CRC). The efficacy of COX inhibitors (coxibs) for 
successfully reducing CRC recurrence further confirmed the key role of COX-2. Alas, 
continuous COX-2 inhibition may increase the risk of a cardiovascular event. Currently, 
little information is available on how inter-individual variations in colon microbiota 
impact coxib disposition and overall celecoxib disposition.  
Objectives  
This project evaluated the effect of clinical concentrations of celecoxib on the in vitro 
colon microbiota. We determined the baseline microbiota activities and metabolic 
response, to reveal whether microbial drug metabolism impacts the conversion process.   
Methods 
We conducted in vitro batch culture experiments, assessing the potential of human 
faecal microbiota for metabolising celecoxib. Faecal slurries from four volunteers were 
supplied with 100 mg/ml of celecoxib and anaerobically incubated for 16h, to simulate 
the transit time of the proximal colon. Short-chain fatty acids (SCFAs) were considered 
benchmarks of gut microbial functionality and determined by gas chromatography. 
Liquid chromatography-tandem mass spectrometry (LC-MS/MS) was used to determine 
celecoxib recovery. Total RNA was applied to perform qRT-PCR of the bacterial 16S 
rRNA gene and to evaluate the metabolically active population. 
Conclusions 
Our results indicate that celecoxib shifts in vitro fermentation, in a donor-dependent 
manner. Celecoxib significantly decreased total SCFA and butyrate (P < 0.001), but not 
copy number of 16S rRNA gene in all donors. Microbial-derived SCFA, such as 
butyrate, may fuel proliferation of cancer-initiated epithelial cells. This study will 
provide information about the microbiota interplay on the efficacy of colon-targeted 
coxibs.  
 
